Background Left ventricular (LV) diastolic function de-clines with the normal aging process. Because these changes are related to impaired active LV relaxation as well as to structural alterations, we hypothesized that verapamil might improve LV filling in elderly normal subjects compared with young normal subjects.
Improvement of the Age-Related Impairment in
Left Ventricular Diastolic Filling With Verapamil in the Normal Human Heart James A. Arrighi, MD; Vasken Dilsizian, MD; Pasquale Perrone-Filardi, MD; Jean G. Diodati, MD; Stephen L. Bacharach, PhD; Robert 0. Bonow, MD Background Left ventricular (LV) diastolic function declines with the normal aging process. Because these changes are related to impaired active LV relaxation as well as to structural alterations, we hypothesized that verapamil might improve LV filling in elderly normal subjects compared with young normal subjects.
Methods and Results We studied 27 normal volunteers (between 20 and 71 years old), with normal exercise tests and echocardiograms, by radionuclide angiography before and after 3 to 4 days of oral verapamil therapy. Indexes of global LV function were derived from analysis of background-corrected time-activity curves. Subjects were recruited from three age groups: young (26±4 years, n=10), middle-aged (46±5 years, n=9), and elderly (66±3 years, n=8). Baseline resting heart rate, blood pressure, peak systolic wall stress, and LV ejection fraction did not differ among groups. Baseline peak LV filling rate (expressed in fractional stroke volume per second) was reduced in the middle-aged group (5.8±1.2, P<.01) and the elderly group (4.3± 1.0, P<.01) compared with Tnhe normal aging process is associated with a decline in left ventricular (LV) rapid diastolic filling,'-4 related to an increase in nonuniform regional diastolic function in elderly subjects.3 Observed changes in LV diastolic dynamics include diminished rate and extent of early diastolic filling'-4 and increased atrial contribution to filling.3'5'6 In contrast, LV systolic function at rest appears to be unaffected by aging.'-3 The observed changes in LV diastolic function may be the result of decreased LV distensibility and/or impaired LV relaxation. Animal studies indicate that aging is associated with an increase in interstitial connective tissue in the mammalian heart,7'8 a process that may reduce LV distensibility. Alternatively, alterations in the active process of actin-myosin inactivation may occur secondary to reduced sequestration of Ca'+ by the sarcoplasmic reticulum and subsequent intracellular Ca'+ overload.9-1" This process may result in the observed impairment in LV relaxation time8,9,'2-14 and peak rate of relaxation.8"13 If this is the case, verapamil, a Ca 2 channel blocker, may result in improved LV filling in elderly subjects, even in the absence of cardiovascular disease. In the current study, we used radionuclide angiography to assess LV filling in normal subjects of different ages to determine if verapamil enhances LV filling dynamics in the healthy elderly heart.
Methods Study Subjects and Baseline Studies
Subjects were recruited from three age groups, representing young, middle-aged, and elderly groups for purposes of data analysis. We studied 27 asymptomatic healthy adult normal volunteers by radionuclide angiography. The mean ages in years of study subjects in the young (n=10), middle-aged (n=9), and elderly (n=8) groups were 26±4, 46±5, and 66±3 years, respectively (Table 1) . These subjects volunteered for this investigational protocol after informed consent was obtained. After an initial blood pressure (BP) screening, subjects were evaluated by medical history, physical examination, serum chemistry, complete blood count, resting ECG, symptomlimited graded exercise ECG according to the Bruce protocol, resting echocardiography, and equilibrium radionuclide angiography at rest and during symptom-limited supine bicycle exercise.
No subject was receiving cardioactive medications, and no subject had evidence of pulmonary, renal, hematologic, or endocrine disorders. Exclusion criteria included a systolic blood pressure (SBP) > 140 mm Hg or diastolic pressure (DBP) >90 mm Hg at rest, LV wall thickness by echocardiography >13 mm or an LV end-diastolic dimension by echocardiography >60 mm. In addition, subjects were excluded if >0.1 mV horizontal or downsloping ST-segment depression was noted on maximal symptom-limited exercise ECG or if a regional wall motion abnormality was observed by radionuclide angiography at rest or during exercise. In the single individual more than 50 years of age in whom LV ejection fraction (LVEF) did not increase during exercise, exercise thallium scintigraphy was performed and was normal.
Gated Blood Pool Scintigraphy
Radionuclide angiography was performed at rest and during exercise with subjects in the supine position using red blood cells labeled in vivo with 20 to 25 mCi of 9'Tc and a conventional Anger camera equipped with a high-sensitivity, parallel-hole collimator oriented in a modified left anterior oblique position. A total of 7.5 to 10.5 million counts were collected for each rest study. All subjects then underwent maximal supine bicycle exercise, beginning at a workload of 25 W, with a 25 -W increase every 2 minutes. Heart rate and rhythm were recorded continuously, and BP was measured at each stage during exercise. Exercise radionuclide angiographic data corresponded to the final 2 to 2.5 minutes of exercise.
High temporal resolution (50 frames/s) cardiac image sequences were constructed by computer-based ECG gating, with the use of list-mode data acquisition with exclusion of extrasystolic and postextrasystolic cycles and combined forward and reverse gating from the R wave.15 LV time-activity curves, representing relative changes in LV volume during the average cardiac cycle, were generated from the cardiac image sequence after background correction with a fixed LV region of interest, which was constructed manually to conform to the borders of the left ventricle as identified from the end-diastolic image, and stroke volume image. After the region of interest was identified in this manner, the time-activity curve was constructed from the raw image sequence without spatial or temporal smoothing processes.
Analysis of Global LV Function
Indexes of global LV function were derived by computer analysis of the background-corrected time-activity curve. Ejection fraction was computed on the basis of relative end-diastolic and end-systolic counts. Resting peak LV ejection and filling rates were determined by fitting third-order polynomial functions to the ejection and rapid diastolic filling portions of the time-activity curve by a least-squares technique. 15 The time of occurrence of the peak filling rate (PFR) was obtained by setting the second derivative of the polynomial function to zero. Time to PFR was measured relative to end systole (minimal volume on the time-activity curve). Peak ejection and filling rates were computed in LV counts per second, normalized for the number of counts at end diastole and expressed as fractional end-diastolic counts (or end-diastolic volume) per second (EDV/s).
Reproducibility of the radionuclide measurements of LV systolic and diastolic function in our laboratory has been reported previously in a separate group of patients. The average change between studies at rest was 0.6+1.9% for LVEF, 0.01±0.27 EDV/s for peak left ventricular ejection rate, 0.01±0.14 EDV/s for peak LV filling rate, and 0±19 milliseconds for time to peak filling rate (PFR). 16 On the basis on these measurements, a change of greater than 2 SD was considered significant in an individual patient. To minimize the effect of variations in end-diastolic volume and ejection fraction among subjects on calculation of PFR, we also computed PFR relative to LV stroke volume (SV/s). Echocardiography M-mode echocardiographic measurements of LV transverse dimensions were obtained with the ultrasound beam directed just caudal to the tips of the mitral leaflets. The end-diastolic LV dimension was measured at the R wave of the ECG, and Age (years) FIG 1. Line plots show left ventricular peak filling rate and time to peak filling rate before and after verapamil, plotted as a function of age. Solid lines represent the regression lines before verapamil and dashed lines represent the regression lines during verapamil administration. EDV indicates end-diastolic volume; SV, stroke volume; and PFR, peak filling rate. the end-systolic dimension was measured at the peak of posterior wall motion. Interventricular septal thickness was measured below the tips of the mitral leaflets, and the posterior wall thickness was measured at the level of the mitral leaflets. Peak systolic wall stress was estimated using LV dimensions obtained by M-mode echocardiography within 2 hours of the radionuclide angiogram. BP by cuff sphygmomanometry was recorded during the resting phase of the radionuclide angiogram. An estimate of peak systolic wall stress was calculated using the formula stress=(SBPxLVID) 
Verapamil Administration
After baseline studies were complete, verapamil was administered beginning at 240 mg/d PO in divided doses and was increased gradually as tolerated to a target dose of 480 mg/d. The target dose was reached in all but 3 subjects. One individual in each age group received a final dose of only 240 mg/d because of the development of hypotension and/or higher than first-degree atrioventricular block. Radionuclide angiography was repeated after each subject received what was considered the optimal dose for at least 36 hours. Repeat echocardiographic studies were performed during verapamil in 20 subjects.
Statistical Analysis
All data are expressed as mean+SD of the mean. One-way ANOVA was used to assess the overall level of significance among the three groups. For variables found to be significant by ANOVA, the two-tailed unpaired t test was used for comparisons between groups, and the paired t test was used for comparisons within each group. The Bonferroni method was applied to adjust for the effect of multiple comparisons. All changes with verapamil were computed as postverapamil minus preverapamil. The relations reported between variables were analyzed by linear regression analysis. ANCOVA was used to assess the significance of the verapamil effect on LV PFR in the entire study population by comparing the relation of age and filling rate with and without verapamil. Multivariate analysis was performed using stepwise linear regression with age and sex forced into the model. Regression model assumptions were checked through residual analysis (SAS Computer Package 6.0, SAS Institute, Inc).
Results

Effect of Age on Left Ventricular Function
Under resting conditions, heart rate, BP (systolic, diastolic, and mean), peak systolic wall stress, and LVEF were not significantly different among the groups (Table 1) . LV dimensions by echocardiography also did not differ among groups. PFR, expressed relative to either EDV or SV, was significantly reduced in the middle-aged and elderly groups compared with the young group. In addition, time to PFR was prolonged in the elderly group compared with the young group. Under control conditions, age correlated significantly with PFR (EDV/s, r= -.69; SV/s, r= -.84; both P<.001) and time to PFR (r=.56, P=.002) (Fig 1) .
Effect of Verapamil on LV Function
After verapamil, resting heart rate, LVEF, and LV peak ejection rate did not change in any group. Systolic, diastolic, and mean blood pressures did not change significantly during verapamil administration in any group, although there was a trend toward lower BP in all groups with verapamil. Systolic wall stress, an estimate of LV afterload, did not change significantly in any group. The echocardiographic LV end-diastolic and end-systolic dimensions, LV wall thickness, and left atrial dimension also were unchanged by verapamil. PFR did not change after verapamil in the young group, but increased significantly in the middle-aged and elderly groups ( Table 1 and Fig 2) . Time to PFR decreased significantly after verapamil in the elderly group and did not change in the other two groups. As a consequence of verapamil administration, the differences in PFR (expressed in EDV/s) and time to PFR among groups were no longer significant with verapamil (Table 1 ). Furthermore, verapamil weakened the relation of age to these indexes of ventricular filling, primarily from changes in the older subjects with no change in the younger subjects (Fig 1) . The verapamil effect was significant regarding the changes in PFR in SV/s and time to PFR, controlling for age by ANCOVA (both P<.01; Fig 1) .
Univariate analysis was performed to identify the significant correlates of the primary end-point variable, the change in LV PFR (EDV/s) observed with verapamil. Variables examined were age, sex, LVEF, PFR, time to PFR, heart rate, BP, and LV end-diastolic and end-systolic dimensions. Baseline and verapamil data for each variable (except age and sex) were included in the analysis, along with the magnitude of change in the variable with verapamil. Only two variables were identified as univariate predictors of change in PFR with verapamil: age and baseline LV PFR (in EDV/s and SV/s). Specifically, the magnitude of the change in filling rate after verapamil was significantly related to age (r=.55, P<.01 and r=.43, P<.05 for filling rate in EDV/s and SV/s, respectively) but not related to the change in SBP (r= -.13 and r= -.31, respectively, P=NS).
Multivariate analysis was performed, adjusting for age and sex, on all variables. The following variables were identified as multivariate predictors of the change in LV PFR with verapamil ( Table 2) : time to PFR at baseline, PFR at baseline (SV/s), and ejection fraction at baseline and during verapamil. The total r2 of the model was .69.
If the reproducibility of radionuclide measurements in our laboratory was taken into account, PFR increased in 13 of 17 subjects (76%) in the two older groups (4 subjects did not change beyond the reproducibility limits), whereas young subjects showed no consistent change after verapamil (no change 5, increase 3, decrease 2; Fig 1) . Representative LV time-activity curves from a young and an elderly subject are shown in 
Subgroup Analysis in Subjects Without
Verapamil-Induced BP Reduction
To minimize the potential effects of BP changes on LV filling, we examined data in the subgroup of subjects in whom the verapamil-induced reduction in SBP was <4 mm Hg. Subjects were divided into younger (age 27±4 years, n=5) and older (age 51±10 years, n=7) groups. Baseline resting BP (systolic, diastolic, and mean), heart rate, peak systolic wall stress, LVEF, and peak ejection rate were comparable in both groups. Baseline PFR was reduced significantly in the older group. After verapamil, there was no change in either systolic or mean BP or peak systolic wall stress in either group. There was a trend toward decreased DBP in both groups. Resting heart rate declined in the older group, whereas LVEF remained unchanged in both groups. Despite this reduction in heart rate, which itself would reduce PFR,2'19,20 PFR increased significantly during verapamil in the older group (2.5 +0.8 to 3.0±0.9 EDV/s, P<.01 and 4.9±1.0 to 5.8+1.1 SV/s, P<.01), whereas it did not change in the younger group, mirroring the results of the entire study population. Time to PFR did not differ between the two groups and was not affected by verapamil in either group. There were no differences in echocardiographic dimensions between groups before verapamil nor were there changes within either group during verapamil.
Discussion
LV diastolic function is influenced by age. Numerous echocardiographic and radionuclide angiographic studies have demonstrated age-related decreases in the rate and extent of early rapid diastolic filling'-4 and increases in atrial contribution to filling.35,6 These changes are similar to those observed in patients with coronary artery disease,2' systemic hypertension,22 and hypertrophic cardiomyopathy.23 However, LV diastolic function declines as a function of age even in subjects without these conditions.13 '24 The data in the present study confirm these earlier results. The mechanism for this decline in humans is not known, but experimental studies suggest two possibilities. Aging is associated with an increase in interstitial connective tissue in mammalian myocardium, which may result in reduced LV distensibility.7'8 Alterations of LV filling arising from such anatomic changes would not be expected to be acutely reversible.
The other possible mechanism involves ventricular relaxation, which is an active, energy-requiring process. 25, 26 The major energy-requiring cellular processes involved in relaxation are the Ca21 pump of the sarcoplasmic reticulum and the Na+-Ca2' exchange pump across the sarcolemma, both of which function to re-store intracellular Ca2+ levels after systolic contraction has occurred.25 Depressed Ca21 pump function, either through depletion of high-energy phosphates, as might occur during ischemia, or through primary alterations in the complex pump-related cellular proteins, would be expected to interfere with the relaxation process. Impairment of these mechanisms may contribute to the diastolic dysfunction observed in ischemic heart dis-ease27 and hypertrophic cardiomyopathy. 28 In addition, there is evidence that these mechanisms may become impaired with aging, leading to a relative intracellular Ca 2 overload.9-1" If the observed age-related decline in diastolic function is due at least in part to alterations in these cellular processes, then Ca 2 channel blocking agents such as verapamil might be expected to improve LV filling in elderly subjects.
The data in the present study demonstrate that verapamil selectively enhances LV diastolic filling in middleaged and elderly subjects, compared with young adults, without affecting systolic function. Our observations support the hypothesis that the impaired LV filling that accompanies the normal aging process is, at least in part, a reversible phenomenon. Although our results using noninvasive techniques in healthy volunteers cannot define the mechanism for the verapamil effect, our results are compatible with the concept that impaired myocardial relaxation, arising from altered intracellular Ca 2 metabolism may be compensated partly by verapamil's cellular effects, which include a reduction in the transmembrane Ca'+ conductance, possibly mediated by the interaction of verapamil with receptors located on the sarcolemma29 or through intracellular effects of verapamil on cardiac sarcoplasmic reticulum. 30 It is important to emphasize that alterations in LV loading parameters secondary to verapamil, rather than a direct myocardial effect, also may contribute significantly to the observed enhancement of LV filling. During the rapid filling phase of diastole, the major loading parameters include ventricular deformation during contraction, afterload, and myocardial wall tension at the time of mitral valve opening and onset of filling.31 These loading parameters may affect the early DP gradient between the left atrium and left ventricle, ultimately influencing the PFR.32 Because LV systolic function and ventricular size were comparable in all subjects, it is unlikely that differences in LV contraction were responsible for the observed changes in ventricular filling.
Changes in afterload are more difficult to exclude and may contribute to the observed changes in LV filling. If a conservative statistical approach is used, there were no significant reductions in BP with verapamil in any group, and the magnitude of the observed changes in filling rates was not related significantly to the magnitude of the BP change. In addition, our estimate of peak systolic wall stress did not change significantly in any group. Finally, the potential effect of BP changes on ventricular filling was minimized by analyzing the subgroup of subjects in whom there was only a minimal change in SBP with verapamil (Table 3 ). In these subjects, verapamil improved LV filling only in the older individuals, mirroring our results in the overall study population. There was a trend toward reduced DBP in all groups, which may, through alterations in endsystolic volume, affect LV filling rate.33 However, this reduction was similar in all age groups, whereas the changes in ventricular filling indexes occurred only in the older subgroups (Tables 1 and 3) .
Although these observations reduce the likelihood of verapamil-induced alterations in afterload, we cannot exclude the possibility that the verapamil effect is mediated through subtle changes in afterload that were not detected by our methods. Since peak LV systolic pressure can occur late in systole in elderly patients,34 our estimate of systolic stress may not reflect true peak systolic stress in all patients. However, precise measurements of LV or aortic pressure throughout the cardiac cycle would not have been practical in normal volunteers. Subtle changes in afterload also may occur because of possible systemic effects of verapamil on the sympathetic nervous system. It has been proposed that the mechanism of action of systemic verapamil on ventricular diastolic function is a reduction in peripheral resistance with a reflex increase in sympathetic tone,35 in turn affecting inactivation-dependent LV relaxation. 36 This mechanism is made less likely by the relative insensitivity of the elderly heart to sympathetic stimulation in comparison with the younger heart.3738 However, an earlier experimental study demonstrated that sympathetic-mediated shortening of contraction duration is preserved in aged rat hearts.39 Although this mechanism could explain our results, reflex sympathetic activation would be expected to enhance diastolic filling in younger subjects as well as in older subjects, which was not observed in our study.
LV contractility and preload also can affect the atrioventricular pressure gradient and must be considered in the interpretation of our ventricular filling measurements. Because LVEF, ejection rate, and endsystolic dimension did not change during verapamil administration, alterations in contractility are less likely. An increase in LV preload cannot be excluded as a potential mechanism for the verapamil effect, although the absence of change in LV end-diastolic dimension, as well as atrial dimension, minimizes this possibility.
Despite the inability to define the mechanism of the verapamil effect, the demonstration of reversal of the age-related impairment in LV diastolic filling has clinical importance. Similar improvements in LV diastolic filling with verapamil have been demonstrated in patients with hypertrophic cardiomyopathy23 and hypertension. 40 In the former condition, this improvement in ventricular filling has been associated with increased exercise tolerance.41 By selection, our study population was free of hypertension or LV hypertrophy, two conditions that develop commonly as a part of the normal aging process. 42, 43 The effects of increased afterload or hypertrophy (or both) on ventricular relaxation and filling dynamics, superimposed on the effects of aging per se, may place some elderly individuals at risk of developing symptoms of pulmonary congestion despite normal systolic function. 44 This would be the case particularly if the BP elevation or the extent of hypertrophy were severe. 45 The understanding that the agerelated decline in LV diastolic function is, at least in part, a reversible phenomenon independent of BP or LV mass may have clinical relevance in the management of the elderly patient with dyspnea and preserved systolic function.
